secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001174947-24-000144
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED Q4 sales $327M (+30.4% YoY); adjusted EPS $1.06 (+152%); guides FY24 rev $1.34-1.365B
--------------------------------------------------------------------------------

- Q4 sales $327.0M, +30.4% YoY (31.5% constant currency); domestic +33.3%, intl +26.5% as reported.
- Q4 GAAP diluted EPS $1.05; adjusted diluted EPS $1.06, up 152.4% vs Q4 2022.
- FY2023 sales $1,244.7M (+19.1%); GAAP EPS $2.04 vs loss of $2.68; adjusted EPS $3.45 (+30.2%).
- FY2024 revenue guidance $1.340B-$1.365B (8-10% growth); adjusted EPS guidance $4.30-$4.40 (25-28% growth).
- Record revenue achieved in both Q4 and full year; balanced growth across General Surgery and Orthopedics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000117494724000144/0001174947-24-000144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000117494724000144/form8k-31428_cnmd.htm
  HTML page:      https://secwatch.observer/filing/0001174947-24-000144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer